{"id":4074,"date":"2012-08-29T11:30:19","date_gmt":"2012-08-29T02:30:19","guid":{"rendered":"http:\/\/www.pharm.kyoto-u.ac.jp\/research\/research-profile\/yakugaku\/"},"modified":"2021-05-26T14:58:15","modified_gmt":"2021-05-26T05:58:15","slug":"bs","status":"publish","type":"page","link":"https:\/\/www.pharm.kyoto-u.ac.jp\/en\/research\/research-organization\/research-profile\/bs\/","title":{"rendered":"Division of Biomedical Sciences"},"content":{"rendered":"\n\n\n\n\n\n\n\n\n
Departments Leaders<\/th>\nResearch Fields<\/th>\nResearch Profile<\/th>\n<\/tr>\n
Drug Delivery Research<\/a><\/p>\n

Professor<\/p>\n

Fumiyoshi YAMASHITA<\/p>\n

 <\/p>\n

 <\/td>\n

\n
    \n
  1. Development of novel nano-DDSs for better therapeutic outcomes<\/li>\n
  2. Association analysis of pharmacokinetics and toxicokinetics of nano-DDSs with their physicochemical properties<\/li>\n
  3. Research on DDS technology for cell-based medicine<\/li>\n<\/ol>\n<\/td>\n
\"\"<\/a><\/td>\n<\/tr>\n
Clinical Pharmacy and Education<\/p>\n

Associate Professor
\nAtsushi YONEZAWA<\/p>\n

 <\/td>\n

\n
    \n
  1. Clinical pharmacological research for a personalized treatment with therapeutic antibody drugs.<\/li>\n
  2. Involvement of renal organic cation transporters involved in the side effects of drugs<\/li>\n
  3. Identification of novel riboflavin transporter RFVT and pathophysiology of rare diseases BVVLS<\/li>\n<\/ol>\n<\/td>\n
\"\"<\/a><\/td>\n<\/tr>\n
Patho-Functional Bioanalysis<\/a><\/p>\n

Professor
\nMasahiro ONO<\/p>\n

 <\/td>\n

\n
    \n
  1. Development of molecular probes for the in vivo analysis of biological function, etiological mechanisms, and action mechanisms of drugs<\/li>\n
  2. Development of radiopharmaceuticals for functional diagnosis and radionuclide therapy<\/li>\n
  3. Clarification of the biological actions of trace metals and development of physiologically active metals complexes<\/li>\n<\/ol>\n<\/td>\n
\"\"<\/a><\/td>\n<\/tr>\n
Biopharmaceutics and Drug Metabolism<\/a><\/p>\n

Professor
\nYoshinobu TAKAKURA<\/td>\n

\n
    \n
  1. Development of drug delivery system using exosomes<\/li>\n
  2. Establishment of immunotherapy based on gene delivery technology<\/li>\n
  3. Development of delivery systems of proteins and nucleic acid drugs utilizing nucleic acid-based nanostructures<\/li>\n
  4. Development of multifunctional cell therapeutics for in vivo cell therapy<\/li>\n<\/ol>\n<\/td>\n
\"\"<\/a><\/td>\n<\/tr>\n
Molecular Pharmacology<\/a><\/p>\n

Professor
\nShuji KANEKO<\/p>\n

 <\/td>\n

\n
    \n
  1. Physiology, pathology, molecular mechanisms, pharmacology, ligand screening and genome science with respect to the membrane transport proteins, especially toward TRP channels<\/li>\n
  2. The roles of neuron-glia-immune cell interaction in CNS pathology and drug action<\/li>\n
  3. Substantial background of pain and action mechanism of analgesics<\/li>\n
  4. Molecular and cellular mechanisms of drug actions and aversive effects<\/li>\n<\/ol>\n<\/td>\n
\"\"<\/a><\/td>\n<\/tr>\n
Clinical Pharmacology and Therapeutics<\/a>
\n(University Hospital)Professor
\nKazuo MATSUBARA<\/td>\n		\n
    \n
  1. Reverse translational research for adverse effects of anti-cancer drugs: elucidation of the mechanisms and development of novel preventive and treatment strategies<\/li>\n
  2. Clinical and basic studies on Pharmacokinetics and Pharmacodynamics<\/li>\n
  3. Molecular and neural mechanisms underlying pathological pain and dysesthesia<\/li>\n
  4. Study of the pathogenic mechanism of Parkinson\u2019s disease in order to identify a potential novel cure<\/li>\n
  5. Application of biomarkers to individualized pharmacotherapy<\/li>\n<\/ol>\n<\/td>\n
\"\"<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n","protected":false},"excerpt":{"rendered":"

Departments Leaders Research Fields Research Profile Drug Delivery Research Professor Fumiyoshi YAMASHITA &nbs […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":3157,"menu_order":50,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"_bbp_topic_count":0,"_bbp_reply_count":0,"_bbp_total_topic_count":0,"_bbp_total_reply_count":0,"_bbp_voice_count":0,"_bbp_anonymous_reply_count":0,"_bbp_topic_count_hidden":0,"_bbp_reply_count_hidden":0,"_bbp_forum_subforum_count":0,"footnotes":""},"class_list":["post-4074","page","type-page","status-publish","hentry"],"acf":[],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/www.pharm.kyoto-u.ac.jp\/en\/wp-json\/wp\/v2\/pages\/4074","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.pharm.kyoto-u.ac.jp\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.pharm.kyoto-u.ac.jp\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.pharm.kyoto-u.ac.jp\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pharm.kyoto-u.ac.jp\/en\/wp-json\/wp\/v2\/comments?post=4074"}],"version-history":[{"count":5,"href":"https:\/\/www.pharm.kyoto-u.ac.jp\/en\/wp-json\/wp\/v2\/pages\/4074\/revisions"}],"predecessor-version":[{"id":21299,"href":"https:\/\/www.pharm.kyoto-u.ac.jp\/en\/wp-json\/wp\/v2\/pages\/4074\/revisions\/21299"}],"up":[{"embeddable":true,"href":"https:\/\/www.pharm.kyoto-u.ac.jp\/en\/wp-json\/wp\/v2\/pages\/3157"}],"wp:attachment":[{"href":"https:\/\/www.pharm.kyoto-u.ac.jp\/en\/wp-json\/wp\/v2\/media?parent=4074"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}